Key Objectives & Platform - Denali aims to transform lives by delivering biotherapeutics to the whole body, including the brain[11] - The company's TransportVehicle (TV) platform enables systemic delivery of biologics to the brain and other hard-to-target tissues[12, 24] - Denali's TransportVehicle has demonstrated best-in-class properties for brain delivery, modularity, and safety[50] Near-Term Commercial Opportunities - Denali anticipates launching tividenofusp alfa (DNL310) in 2026 and DNL126 in 2027, establishing a commercial foundation for the Enzyme TransportVehicle (ETV) franchise[13] - Tividenofusp alfa has a PDUFA target action date of April 5, 2026, for accelerated approval[61, 81] - The ETV franchise targets lysosomal storage disorders (LSDs), with a combined market opportunity exceeding $1 billion for MPS II and MPS IIIA[13, 107] Pipeline & Milestones - Denali has a broad clinical-stage pipeline, including programs for Alzheimer's disease, with several near-term milestones expected[14] - The company anticipates an approval decision for tividenofusp alfa, ETV:SGSH Phase 1/2 data, and initiation of Phase 1 studies for OTV:MAPT, ATV:Abeta, and ETV:GAA in the first half of 2026[16] - Denali is developing the next generation of enzyme replacement therapies designed to treat brain and body manifestations of serious genetic diseases[61, 64] Financial Position - Denali has a strong financial foundation with approximately $873 million in cash and investments as of Q3 2025, plus $488 million from royalty financing and an equity capital raise in December 2025[146]

TG Therapeutics (NASDAQ: TGTX) J.P. Morgan Healthcare Conference Presenter: Michael S. Weiss, Chairman & CEO January 2026 TAKING ON MS Forward Looking Safe Harbor Statement This presentation contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward- looking statements contained in the Private Securities Litigation Reform Act of 1995. Such forward looking statements include but are not limited to statemen ...

Financial Performance and Outlook - Ambarella expects total revenue growth in the 36% to 38% range for F2026, reaching approximately $390 million at the midpoint[40] - Q4 revenue guidance is $97 million to $103 million, with a midpoint of $100 million[40] - Non-GAAP gross margin for Q4 is estimated to be 59% to 60.5%[40] - The company has $295 million net cash with no debt and 16 consecutive years of positive free cash flow[14] - Edge AI 5-Year Revenue CAGR is 64%[15] Market and Technology - Ambarella has shipped cumulatively over 40 million Edge AI SoCs[5] and 400 million SoCs[5] - The Edge AI SAM is projected to grow from $5.5 billion in F2026 to $12.9 billion in F2031, representing an approximate 18% CAGR[31] - IoT applications are estimated to contribute approximately 70% of F2025 revenue[32], with the IoT SAM estimated at $2.5 billion in F2026 and $5.7 billion in F2031[34] - Auto applications are estimated to contribute approximately 30% of F2025 revenue[35], with the Auto SAM estimated at $3.0 billion in F2026 and $7.2 billion in F2031[37] Strategic Initiatives - Ambarella has invested $1.3 billion cumulatively in AI R&D over the last decade[5] - The company's technology portfolio includes 2nm in development, 5nm representing approximately 45% of revenue, and 10nm representing approximately 35% of revenue[14]

January 2026 Investor Presentation Forward-Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the U.S. Securities Exchange Act of 1934 and the Securities Act of 1933. The forward-looking statements include statements concerning, among other things, our future business model and strategies, our financial model and structure, market and market share growth, industry trends, customer demand and growth opportunities. In some instances, you ...

J.P. Morgan 44th Annual Healthcare Conference failure to retain key suppliers; challenges to the future development of our non-insulin drug delivery product line; our failure or that of our contract manufacturer or component suppliers to comply with the U.S. Food and Drug Administration's quality system regulations or other manufacturing difficulties; extensive government regulation applicable to medical devices, as well as complex and evolving privacy and data protection laws; our use of artificial intelli ...

44th Annual J.P. Morgan Healthcare Conference Stefan Oelrich Member Of The Board Of Management Of Bayer AG President Pharmaceuticals January 13th, 2026 Our Strategy is Showing Tangible Results Nubeqa and Kerendia with sustained growth momentum, offsetting Xarelto declines Next wave of growth with Beyonttra, Lynkuet and Asundexian Robust Eylea Franchise and Foundational Business Driver for near-term growth Renew topline Grow pipeline value New Innovation Model yielding success Five new indications or product ...

January 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Disease Renee Gala, President & CEO Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the ability of the Company's portfolio to drive long-term shareholder value; ...

Danaher Corporation Rainer Blair, President & CEO J.P. Morgan Healthcare Conference | January 13, 2026 Innovation at the speed of life. Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher's estimated or anticipated financial performance and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward looking" statements within the meaning of the federal secu ...

Company Overview - Bel Fuse's annual sales are $657 million[6] - Adjusted EBITDA is $137 million, representing 20.9% of sales[6] - Original Equipment Manufacturers (OEM) account for 75% of Bel Fuse's customer base, while distributors make up 25%[10] - North America accounts for 65% of the company's geographic revenue, Asia 19%, and Europe 15%[10] Segment Performance - Power Solutions & Protection revenue was $224.4 million[12] - Connectivity Solutions revenue was $220.4 million[12] - Magnetic Solutions revenue was $210.6 million[12] - Aerospace/Defense TTM revenue was $163.5 million[12] Financial Transformation - Gross Margin has increased from 24.7% in 2021 to 38.7% in TTM Q3-25[14] - Historical Revenue increased from $535 million in 2023 to $657 million in TTM Q3-25[14] - Historical Adjusted EBITDA increased from $101.9 million in 2023 to $137.4 million in TTM Q3-25[18] Growth Drivers - Approximately 40% of Bel's sales support Aerospace & Defense applications[30] - Emerging end markets (Space & AI) have seen significant growth[31]

Financial Performance - The company's LTM 2025 revenue was approximately $40237 billion, with the DSA segment contributing 6001%[13,74] - The company expects to deliver approximately $295 million in cumulative, annualized cost savings by 2026[48] - The company's capital expenditures represented 51% of LTM revenue, compared to a peak of 82% in 2022[54] - Approximately $450 million in stock repurchases were made in 2024-2025[54] Market Position and Strategy - The company supported over 80% of FDA-approved novel drugs in the last five years (2021-2025)[11] - The company estimates the addressable market opportunity to be approximately $25 billion[11] - The company's revenue from the biopharma industry is approximately 70%[9] - The company plans to divest underperforming or non-core assets representing approximately 7% of 2025E revenue[52] Acquisitions and Outlook - The company plans to acquire K.F. (Cambodia) Ltd for approximately $510 million, expected to close in early Q1 2026[53] - The company plans to acquire the remaining 79% equity stake of PathoQuest SAS for approximately $60 million, expected to close by the end of Q1 2026[53] - PathoQuest is expected to generate $15-$20 million in 2026 annual revenue[53]